Auto-Injectors Market Global Outlook 2021 to 2023 | By Industry Analysis

10/feb/2021 09:58:20 Market Research Future Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

MRFR is the Leading Brand in The Research Company Who Recently Published Auto-Injectors Market Research Reports which includes Unique Research information, Market Dynamics, Drivers, and Technology Trends & Assessment by 2023

Auto-Injectors Global Market – Key Players

While commenting upon this deep diving study report, presented through more than 100 market data tables and figures, widely spread over 85 pages, the MRFR Research Analyst also mentions that Auto injectors normally are made of glass syringes making them fragile and a probable cause of contamination. Currently, the players of the market are striving to create auto injectors syringes with plastic to prevent unnecessary contamination, confirms MRFR Analysis.

Get Free Request Sample Report at

MRFR Analysis identifies following corporations as the key players operating in the global market of auto injectors some of them are: UNILIFE CORPORATION, Scandinavian Health Ltd, Owen Mumford Ltd. (UK), kaleo, Inc., Amedra Pharmaceuticals LLC, Enbrel and others.

Segmental Analysis

The autoinjectors market has been segmented on the basis of therapy, type, region, and distribution channel. On the basis of type, the autoinjectors market has been segmented into reusable autoinjectors and disposable autoinjectors. Based on therapy, the market for autoinjectors has been segmented into multiple sclerosis, diabetes, rheumatoid arthritis, anaphylaxis, and others. On the basis of distribution channel, the autoinjectors market has been segmented into hospital pharmacies, retail pharmacies, and others. The autoinjectors market includes regions such as Europe, the Middle East, the Americas, Asia Pacific, and Africa.

Auto-Injectors Market- Overview

Auto-injectors are spring-loaded syringes, designed to deliver a single dose of a particular life-saving drug. Auto injectors, as the name suggests are easy to use and are intended for self –administration by patients or can be administered by untrained personnel. These injectors were initially designed to overcome the hesitation associated with self-administration of the needle-based drug delivery device. Most of the injectors are springe-loaded based.

Auto-injectors not only allow the automatic injection of a syringe but also have a visual indication that confirms the deliverance of the full dose; hence, these are preferred over the traditional syringes involved in the needle-based drug delivery devices. Affirmations stating that the auto-injectors are entirely safe and reliable for the self-administration of drug delivery are driving the growth of the market.

Moreover, the Increasing development and use of biological drugs (biologicals) & vaccines are expected to increase the market size from 2017 to 2022. Besides, factors such as the rising need for targeted and sustained drug delivery in the treatment of chronic diseases and the need for cost-efficient delivery of high-priced medications are fostering the growth of the market.

Additional factors propelling market growth include the rising prevalence of chronic diseases and the augmented demand for intensive care for patients in critical conditions. Moreover, the proliferation of home healthcare-based medical devices that are embedded with sensors is supporting the market allowing patients to self-administer the doses. These advantages are fostering the growth of auto-injectors market to a great deal. Furthermore, the increasing geriatric populace and rapidly changing lifestyle propel the growth of the market.

Industry Updates

Nov 2018 The FDA has approved Genentech’s single-dose, prefilled autoinjector ACTPen 162 mg/0.9 mL of tocilizumab (Actemra) for patients with giant cell arteritis (GCA), rheumatoid arthritis (RA), and 2 forms of juvenile arthritis.

Detailed Regional Analysis

The regional analysis of the autoinjectors market finds that the Americas is estimated to control the global autoinjectors market due to a mature healthcare sector, increasing incidence of autoimmune and chronic diseases, and rising healthcare spending. Moreover, the promising reimbursement scenario in this region adds to the growth of the market. The European region is projected to be the second major market in the autoinjectors market globally.

The market expansion in this region is credited to the rising prevalence of chronic diseases, the availability of funds for research, and growing healthcare expenses. The Asia Pacific is estimated to be the speediest rising region in the market owing to the incidence of a huge patient population, incessantly developing economies, intensifying prevalence of diseases, and escalating government funding for the healthcare sector. Conversely, the Middle East and Africa region has the minimum share of the market. The majority of the market of this region is anticipated to be controlled by the Middle Eastern region due to a sophisticated healthcare sector and mounting government initiatives for the healthcare sector.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures at



About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

blog comments powered by Disqus è un servizio offerto da Factotum Srl